KAT2B and breast carcinoma: This study suggests that PARP inhibitor resistance in BRCA-deficient breast cancer may be due in part to low PCAF levels; PCAF levels could serve as an indicator to assess therapeutic response to PARP inhibition in BRCA-deficient breast and other cancers.